In a systematic review and meta-analysis of nonrelapse mortality (NRM) following CAR T cell treatment in 7,604 patients with lymphoma and myeloma, almost half of cases were atrributable to infections and NRM estimates varied across both tumor types and CAR T cell products
- David M. Cordas dos Santos
- Tobias Tix
- Kai Rejeski